← Back to Search

Procedure

Personalized TMS for PTSD

N/A

Recruiting

Led By Bill Phillips, PhD

Research Sponsored by Wave Neuroscience

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age 22 - 65 years

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up assessed at all treatment sessions and follow-up visit, a duration of up to 5 weeks

Awards & highlights

Study Summary

This trial studies a new treatment for PTSD in veterans and first responders. It involves 20 in-office treatments with EEG recordings to determine optimal treatment parameters.

Who is the study for?

This trial is for U.S. Military veterans or first responders aged 22-65 with PTSD who can consent to participate. It's not for pregnant women, those in other studies, people with uncontrolled health conditions, metal implants in the head, history of ECT/TMS, stroke, seizures or family history of seizures.Check my eligibility

What is being tested?

The study tests EEG-based personalized TMS treatment on participants with PTSD over a course of 20 sessions within 35 days. An initial EEG records brain activity to tailor the TMS therapy specifically for each individual.See study design

What are the potential side effects?

While not explicitly listed here, common side effects from TMS may include headache, scalp discomfort at the site of stimulation, tingling or spasms of facial muscles.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 22 and 65 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ assessed at all treatment sessions and follow-up visit, a duration of up to 5 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~assessed at all treatment sessions and follow-up visit, a duration of up to 5 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and assessed at all treatment sessions and follow-up visit, a duration of up to 5 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Treatment Safety

Trial Design

1Treatment groups

Experimental Treatment

Group I: Open-Label active EEG-based personalized TMS treatmentExperimental Treatment1 Intervention

20 sessions of EEG-based personalized TMS over a maximum of 21 days. Two sessions per treatment day. Each session consists of TMS treatment at 50% Motor Threshold, pulse frequency between 8-13 Hz. TMS delivery of 5 second pulse train, with an inter-train interval of 20 seconds. Session duration is 15 minutes. A rest period of at least 30 minutes is required between the 2 sessions in a treatment day.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Wave NeuroscienceLead Sponsor

12 Previous Clinical Trials

886 Total Patients Enrolled

Bill Phillips, PhDPrincipal InvestigatorWave Neuroscience, Inc.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any remaining opportunities to take part in this trial?

"As indicated on clinicaltrials.gov, this particular medical experiment is not enrolling participants at the moment; however, it was initially posted on October 1st 2023 and recently updated on October 10th 2023. Fortunately, there are 330 other trials actively recruiting patients as of now."

Answered by AI

Are any participants of advanced age involved in this research?

"According to the stated criteria for this trial, individuals who would like to participate must be between 22 and 65 years old. There are 31 trials available for those under 18, while patients over 65 have 268 options."

Answered by AI

Am I an eligible candidate for this scientific exploration?

"Qualified participants for this research project have to be between 22 and 65 yeras old, as well as suffering from post-traumatic stress disorder. A total of 30 individuals are being enrolled in the trial."

Answered by AI

Recent research and studies

Archives of General PsychiatryJournal

Daily Left Prefrontal Transcranial Magnetic Stimulation Therapy for Major Depressive Disorder

George, Mark S., Sarah H. Lisanby, David Avery, William M. McDonald, Valerie Durkalski, Martina Pavlicova, Berry Anderson, et al.. 2010. “Daily Left Prefrontal Transcranial Magnetic Stimulation Therapy for Major Depressive Disorder”. Archives of General Psychiatry. American Medical Association (AMA). doi:10.1001/archgenpsychiatry.2010.46.

Brain StimulationJournal

A Two-site Pilot Randomized 3 Day Trial of High Dose Left Prefrontal Repetitive Transcranial Magnetic Stimulation (rtms) for Suicidal Inpatients

George, Mark S., Rema Raman, David M. Benedek, Christopher G. Pelic, Geoffrey G. Grammer, Karen T. Stokes, Matthew Schmidt, et al.. 2014. “A Two-site Pilot Randomized 3 Day Trial of High Dose Left Prefrontal Repetitive Transcranial Magnetic Stimulation (rtms) for Suicidal Inpatients”. Brain Stimulation. Elsevier BV. doi:10.1016/j.brs.2014.03.006.

Brain and BehaviorJournal

Concomitant Medication Use and Clinical Outcome of Repetitive Transcranial Magnetic Stimulation (rtms) Treatment of Major Depressive Disorder

Hunter, Aimee M., Michael J. Minzenberg, Ian A. Cook, David E. Krantz, Jennifer G. Levitt, Natalie M. Rotstein, Shweta A. Chawla, and Andrew F. Leuchter. 2019. “Concomitant Medication Use and Clinical Outcome of Repetitive Transcranial Magnetic Stimulation (rtms) Treatment of Major Depressive Disorder”. Brain and Behavior. Wiley. doi:10.1002/brb3.1275.

BMC PsychiatryJournal